GWPH.US
id: 629
GW Pharma (GWPH) M&A $7.75M Settlement
S.D. California
Court3:21-cv-01019
Case number03/10/2021
Class period Start05/05/2021
Class period End01/08/2024
Claim deadlineGW Pharma (GWPH) agreed to pay $7.75 million to Investors to avoid further litigation.
Investors who purchased, sold, or held $GWPH at any time during the period from and including March 10, 2021, through and including May 5, 2021, may be affected by the Settlement of this Litigation.
- On February 3, 2021, GW entered into a merger agreement where GW ordinary shareholders would receive $16.66 in cash and $Jazz shares based on an exchange ratio calculated from Jazz's share price, while GW American Depositary Shares holders would receive approximately $200 per share in cash and $20 in Jazz stock;
- However, shareholder complaint alleged that $GWPH disseminated a materially false and misleading Definitive Proxy Statement to persuade GW shareholders to vote in favor of the Merger, containing inaccuracies regarding GW's financial projections, stock value, and the fairness of the Merger Consideration.
Case Status
Disbursed
Alleged Offence
Misleading Statements,
Failure to Disclose,
Omissions
Suspected Party
Directors,
Management
Security Type
Depository Securities (ADS, ADR, GDR)
Trade Direction
Long
Payout per Share
0.25
Filing date
05/27/2021
Lead Plaintiff Deadline
08/03/2021
Plaintiffs
Kurt Ziegler
Attorneys
Kahn Swick & Foti, LLC (New Orleans, LA), Monteverde & Associates PC (Culver City, CA)
Defendants
Geoffrey W. Guy, Justin Gover, Cabot Brown, David Gryska, Catherine Mackey, James Noble, Alicia Secor, Lord William Waldegrave
Judge
Hon. Cynthia Bashant
Administrator
Rust Consulting
Settlement agreement date
2023-03-16
Court hearing date
12/11/2023
Exclusion deadline
11/20/2023
Objection deadline
11/20/2023
Hearing deadline
11/20/2023
Attorney fee
$0.09
Trades matching type
FIFO
Disbursement date
08/08/2024
+$7,750,000
Cash Settlement Amount